XML 73 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Disaggregation Of Revenue [Line Items]    
Primary sources of revenue, description We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other).  
Revenue recognized $ 1,300  
Deferred revenue $ 324 $ 962
Revenue | Minimum | Customer Concentration Risk | Medicare    
Disaggregation Of Revenue [Line Items]    
Concentration risk, percentage 43.00% 37.00%
Other Long-term Liabilities    
Disaggregation Of Revenue [Line Items]    
Non-current deferred revenue $ 300 $ 400
Up Front Cash Payments    
Disaggregation Of Revenue [Line Items]    
Deferred revenue $ 600